Although recurrent microaspiration of refluxed gastric fluid ("GER with microaspiration") is suspected in the onset and course of many diseases of the lungs and airways, the lack of a non-invasive, direct test for its occurrence has hampered research on its importance. Complicating assessment is its nocturnal occurrence, when sleep interferes with protective reflexes. The tests currently available, esophageal manometry and 24h pH monitoring, or scintigraphy, are expensive, technically difficult and indirect, or involve radioactive material. We have identified two compounds poorly absorbed systemically after ingestion;both are approved for human use and have few side effects. One is well absorbed from the lungs and airways and excreted in urine. The other is not absorbed from the lungs and airways, but can be prepared in monodisperse insoluble particles. We accordingly propose to examine whether overnight oral administration of the first drug results in greater quantities being detected in urine from 10 patients thought to have recurrent GER with microaspiration than from 5 healthy controls. We also propose to examine in the same subjects whether administration of the second substance as a suspension of particles results in different quantities being detected in sputum collected overnight and induced the following morning. We will examine the concordance of the findings when the drugs are given together - the particles of the second substance suspended in a solution of the first. If this pilot study is promising, we will propose Phase II studies to refine the methods and examine them in larger numbers of subjects.

Public Health Relevance

Microaspiration of gastric fluid into the respiratory tract (GER with aspirations) is suspected to be the cause of multiple severe respiratory diseases, yet there is no simple non-invasive method for routine clinical practice to detect this problem and investigate the results of interventions to stop it. We are developing a simple method based on ingestion of an oral liquid preparation containing two safe non-radioactive markers administered at night followed by urine and sputum collection to detect the markers of aspiration. If we find a significant difference between patients known to have GER with aspirations and healthy subjects with either of the two markers, we plan to make this diagnostic method commercially available for routine clinical practice.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43HL120427-01
Application #
8591417
Study Section
Special Emphasis Panel (ZRG1-CVRS-H (11))
Program Officer
Eu, Jerry Pc
Project Start
2013-08-05
Project End
2014-07-31
Budget Start
2013-08-05
Budget End
2014-07-31
Support Year
1
Fiscal Year
2013
Total Cost
$339,824
Indirect Cost
Name
Aradigm Corporation
Department
Type
DUNS #
792998783
City
Hayward
State
CA
Country
United States
Zip Code
94545